Sicor and BioGeneriX to Develop Generic Biopharmaceuticals

An agreement to jointly develop and market a recombinant protein pharmaceutical has been announced by Sicor, Inc. (Irvine, CA, USA; www.sicor.com) and BioGeneriX AG (Mannheim, Germany; www.biogenerix.com).

The pharmaceutical will be manufactured and produced by Sicor and marketed in Europe by BioGeneriX's parent company (ratiopharm), following regulatory approval. BioGeneriX will receive a royalty on Sicor's sales in North and Central America. Financial terms were not disclosed.

Sicor is a multinational pharmaceutical company focused on generic injectable pharmaceuticals and generic biopharmaceuticals, concentrating on products and technologies that present significant barriers to entry or that offer first-to-market opportunities. BioGeneriX specializes in the development of biopharmaceutical drugs with known mode of actions and established markets for ratiopharm and other global partners.

"This collaboration provides access to European markets through the BioGeneriX clinical development program and ratiopharm's sales force while simultaneously giving Sicor the potential to expedite its entry into North American biopharmaceutical markets,” said Marvin Samson, president and CEO of Sicor.





Related Links:
Sicor
BioGeneriX